Src, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma

BACKGROUND: Src is a non-receptor tyrosine kinase involved in signalling and crosstalk between growth-promoting pathways. We aim to investigate the relationship of active Src in response to trastuzumab of HER2-positive breast carcinomas. METHODS: We selected 278 HER2-positive breast cancer patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Peiró, G, Ortiz-Martínez, F, Gallardo, A, Pérez-Balaguer, A, Sánchez-Payá, J, Ponce, J J, Tibau, A, López-Vilaro, L, Escuin, D, Adrover, E, Barnadas, A, Lerma, E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4134494/
https://www.ncbi.nlm.nih.gov/pubmed/24937674
http://dx.doi.org/10.1038/bjc.2014.327

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4134494/
https://www.ncbi.nlm.nih.gov/pubmed/24937674
http://dx.doi.org/10.1038/bjc.2014.327

Ejemplares similares